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Introduction
The use of exogenous estrogen and progesterone therapy among postmenopausal women and the subsequent risk of breast cancer remains a very controversial subject. There is little consistency in relative risks (RR) of hormone replacement therapy (HRT) and breast cancer across many studies (1) . The widespread and increasing use of HRT could be of major concern if such therapy was actually associated with an increased risk of breast cancer. There are several factors that could account for inconsistent study results on the relationship between exogenous hormone therapy and risk of breast cancer. The first and most important is probably selection bias among postmenopausal women given HRT. Women at lower risk for breast cancer are more likely to be placed on HRT (2) .
Second, the duration of follow-up for women on HRT has not been long enough to identify either a morbidity (i.e., an increase in incidence) or increased mortality from breast cancer (3) . A third hypothesis is that estrogen or estrogen/progesterone therapy is not an important determinant of the risk of breast cancer (4) .
In this paper we will briefly review the model for the development of breast cancer among postmenopausal women. Using data from the Study of Osteoporotic Fracture (SOF) we measured the relationship between bone mineral density (BMD) and risk of breast cancer. We then modeled the potential risk of breast cancer for women on HRT based on BMD as a selection criteria. We also investigated whether changes in the selection criteria for HRT use (that is, placing women who have high BMD, high body weight, or high lipid levels on HRT) could increase the estimated risk for breast cancer.
A plausible hypothesis linking host susceptibility, environmental agents, and hormones to the risk of breast cancer is as follows: a) The early neoplastic changes of breast cancer are caused by exposure to a variety of chemical carcinogens that are secreted by breast glandular tissue. The exposure is more important at an earlier age (5, 6) . Susceptibility of breast tissue to specific agents is clearly age dependent, as suggested by the substantially reduced risk of breast cancer at first full-term pregnancy. This is probably due to differentiation of breast glandular tissue, and differences in the risks of breast cancer related to age with exposure to radiation (a causal agent for breast cancer) (7) . b) The growth of breast neoplasms to clinical disease is primarily determined by sex steroid hormone levels, especially estrogens, and estogen metabolism (5, 8, 9) . c) The progression to metastatic disease may be related to a secondary exposure to carcinogens in cells with higher mitotic activity secondary to hormone stimulation later in life (5) . d) Genetic host susceptibility plays an important role, possibly related to the metabolism of the carcinogens, such as P450 polymorphisms (10, 11) , genetic polymorphisms that affect sex steroid hormone metabolism or receptors (12) , or mutations in oncogenes or suppressor genes such as p53-as yet unknown effects related to BRCA (13) .
Endogenous Estrogen and Breast Cancer
The levels of endogenous estrogen exposure at the breast and the specific metabolites of estrogen (14) (14) .
The level of estrogens and progesterone are much higher among pre-as compared to postmenopausal women (15, 16) . The variability of blood estrogen levels during the menstrual cycle has made it extremely difficult to evaluate the relationship between premenopausal blood estrogen levels and the risk of breast cancer (16, 17) . It is unclear whether peak estogen levels during the menstrual cycle, average estrogen levels over the cycle, or perhaps, levels during the luteal or follicular phases are important risk factors for breast cancer.
The importance of endogenous estrogen levels and risk of premenopausal breast cancer are primarily documented by the substantial reduction in risk associated with oophorectomy (18) (especially at an early age), and the benefits of oophorectomy (19) and tamoxifen (20) (21) . The primary estrogen in postmenopausal women is estrone, which is not bound to sex hormone-binding globulin. A small amount of testosterone is also produced for a period of time by the postmenopausal ovary (22 (23) .
The levels of estrone and estradiol early in the postmenopause (first several years after the menopause) are related to residual ovarian secretion of estrogens, as well as the aromatization of androstenedione (15, 16, 24) . Estradiol levels early in the postmenopause correlate poorly with levels later in menopause and there is no apparent relationship between estrogen levels in premenopause and levels in the same women in postmenopause (24) . Postmenopausal estradiol levels are not related to premenopausal level nor to the levels early in the postmenopause.
Estradiol is weakly bound to sex hormone-binding globulin and recent interest has focused on whether the free estradiol levels may be a better measure of risk of breast cancer. Free levels of estradiol are extremely difficult to measure accurately among postmenopausal women. Levels of sex hormone-binding globulin may be used to estimate the percentage of free estradiol (25) .
Endogenous Estrogens and Other Biological Associations
The measurement of postmenopausal estrogen levels do appear to have other biological associations in addition to possible risk of postmenopausal breast cancer. Women who report hot flashes during the perimenopause and early in the postmenopause have lower blood estradiol levels (26) . A positive association has been noted between blood estradiol and estrone levels and BMD among postmenopausal women that appears to be independent of obesity (27) . There is a suggestive association of higher estradiol and lower low-density lipoprotein cholesterol (LDLc) levels among postmenopausal women (28) .
There have been both case-control and longitudinal studies of the association of endogenous estrogen levels and risk of breast cancer (1, 4, 5) . The results of these studies are inconsistent. More recent prospective studies have documented an increased risk of breast cancer with higher levels of postmenopausal blood estrogens, especially free or non-sex hormone-bound estradiol levels (29) .
However, all of the associations between blood estrone and estradiol levels and biological measurements (breast, bone, hypertrophy, lipids) are relatively weak, due to the variability of the measurements of estrone and estradiol. The blood levels are a measure of production, secretion, and metabolism of estrogens (16) . Estrogen levels at specific tissue such as the breast may not necessarily be measured by blood levels (30) . Fat tissue in the breast can aromatize androstenedione to estrone and then to estradiol. Sulfatases, also in the breast, can convert estrone sulfate to estrone. Therefore, exposure of the postmenopausal breast to estrogens is certainly higher and may be quite different from levels reported in the blood (5, 31) . It is extremely difficult to measure estrogen levels in breast tissue in epidemiological studies among postmenopausal women, especially in prospective studies where large numbers of healthy women must be followed over a long period of time.
Determinants of Endogenous Estrogens
The primary determinants of postmenopausal estrone and estradiol levels are obesity or body fat. In the Healthy Women Study we showed that postmenopausal levels (5-8 years postmenopausal) of both estrone and estradiol were directly related to body mass index (BMI) (28) . The strong association between BMI and postmenopausal estrone and estradiol levels has been documented in many epidemiological studies (5) . Several studies show an association between obesity among postmenopausal women and risk of breast cancer (5) .
Obesity and body fat distribution are major determinants of sex hormone-binding globulin. The sex hormone-binding globulin levels decrease substantially with increasing levels of obesity among postmenopausal women (32) . The degree of obesity (33) , the amount of intraabdominal fat, and the waist-to-hip ratio (34) have all been related to the increased risk of breast cancer. The levels of sex hormone-binding globulin and any relationship to breast cancer may, therefore, be only a measure of the degree of obesity and the high correlation with levels of sex hormone-binding globulin.
Estradiol is also more weakly bound to sex hormone-binding globulin than testosterone (32) . The levels of sex hormone-binding globulin may be a measure of the relative amount of free testosterone to free estradiol. This ratio (estradiol/ testosterone) could be related to risk of breast cancer. Recent studies have shown that higher free testosterone levels in postmenopausal women are risk factors for breast cancer (35 (36) .
Bone contains estrogen receptors and is highly sensitive to estrogen levels (37) . Early age at menarche, length of reproductive life, and normal cycling are associated with higher BMD (38) .
The peri-to postmenopause is associated with substantial bone loss due to the decrease in estrogen production by the ovary (39) . As noted, we have found that endogenous estrogen levels are independently related to BMD among older women (27) . Estrogen drug therapy and resulting higher blood estrogen levels are also associated with a decrease in the rate of bone loss and fractures among older women (40) . Greater degrees of obesity and higher estrogen levels correlate with higher BMD, even for nonweight-bearing sites (27 Medical records for all breast cancer cases were reviewed to validate the diagnosis. Four of the 121 breast cancer cases were considered carcinoma in situ (41) .
BMD was measured at entry to the study using an Osteo analyzer (Siemens Osteon, Wahiwa, HI). The distal and midradius and the calcaneus were scanned at the baseline examination. During a second clinical examination (approximately 2 years after baseline), measurements of BMD at the proximal femur and lumbar spine (L1-4) using Dual Energy X-ray Absorptiometry (DEXA) 1000 (Hologic, Waltham, MA) were added (42) . Both measurements are associated with relatively small coefficients of variation of the measurements (1.5% distal radius, 2.0% midradius, 1.3% calcaneous, 1.2% femoral neck and 1.5% lumbar spine) (42) .
The study included information about weight, height, self-reported height at age 25 years, reproductive history, family history of breast cancer, and history of benign breast disease. Blood samples were also obtained and are currently being analyzed for sex-steroid hormone levels (41) .
Results
The age-specific incidence rates (95% CI) of breast cancer (per 1000 person years) were (n= 56) 4 increases the risk of breast cancer among women with low BMD and estrogen deficiency relative to that of all other women, and would have little effect on women who already had high BMD. If this model were true, women with low BMD, even with a 3-fold increased risk of breast cancer, would not be identified in current epidemiological studies; the overall risk associated with HRT compared with non-HRT for the entire population would only be a 1.4-fold increased risk, similar to that found in many of the current studies, unless measures of BMD were available.
The increased risk of breast cancer may be greater in women with high BMD and more than additive. If such a situation exists, it is possible that there may be a group of women at extremely high risk of breast cancer who might inadvertently be placed on HRT for cardiovascular protection and be at extremely high risk of breast cancer.
Discussion
Why exogenous estrogens or estrogen/ progesterone, i.e., in HRT, are not associated with a substantial increased risk of breast cancer among postmenopausal women, given that endogenous estrogens are an important determinant of breast cancer, is a major unanswered question. Possible explanations for the failure to document an increased risk of breast cancer among HRT users has focused on several areas: a) The In recent years, the current use of HRT for the prevention of cardiovascular disease and osteoporosis, as well as a shorter term use for the treatment of menopausal symptomatology and estrogen deficiency has greatly increased the population of women on HRT. Women now remain on HRT for longer periods of time and start therapy soon after the menopause, in order to reduce the risks of both coronary heart disease and osteoporosis.
The combination of long-term use and therapy initiation fairly early after the menopause will ultimately result in many more long-term estrogen or estrogen/ progesterone users. Furthermore, whereas women were selected for HRT in the past based on relative estrogen deficiency, many of the current potential long-term users are being placed on therapy for prophylaxis, especially for coronary heart disease and osteoporosis. This presents an interesting problem, because obese women are more likely to have lower HDLc and higher LDLc after the menopause and, therefore, would be considered to be candidates for hormone replacement therapy (51) . However, such women probably have higher estrogen levels, especially if they gained weight from the pre-to the postmenopause, resulting in an increase in their LDLc, decrease in their HDLc, and possibly an increase in their risk of breast cancer. It is possible that women at greater risk of breast cancer because of long-term higher levels of endogenous estrogens, are now being exposed to further high levels of estrogens with estrogen/progesterone therapy.
The increased risk of breast cancer in older women associated with higher BMD and presumably increased endogenous estrogen exposure may not result in metastatic disease or substantial morbidity or mortality. It is possible that without further exposure to other carcinogens or a genetic susceptibility to metastatic disease, the breast cancers identified primarily by mammography among older women are of little clinical importance.
There could be an important interaction between stimulants of breast glandular epithelial cells by estrogen and exposure to carcinogens. The progression to metastatic disease may be linked to either further exposure to carcinogens or genetic host susceptibility, including metabolism of estrogen such as through 2-and 16a-hydroxylation of estrone (9) .
Current clinical trials, including the Women's Health Initiative (i.e., very low fat/high fiber intake) (52), the tamoxifen trial (the primary prevention of breast cancer in high risk women) (53) and trials of luteinizing hormone-releasing hormone antagonists among women at very high risk of premenopausal breast cancer (54) , have the potential for substantially modifying the risk, primary prevention, and decreased incidence of breast cancer. The difficulties in maintaining long-term weight reduction, especially among postmenopausal women, have precluded very important trials of the effects of weight loss among postmenopausal women and the risks of breast cancer.
Potential risks are associated with the reduction of endogenous estrogen levels across the population, since BMD is directly related to endogenous estrogen levels. Reduction of estrogen levels may result in decreased BMD and an increase in risk of osteoporotic fractures. Similarly, high endogenous estrogen levels among postmenopausal women may provide protection against cardiovascular disease and reduction of these levels could be associated with an increase in coronary heart disease.
It has taken at least 15 years to recognize the association between estrogen therapy and uterine cancer. The use of HRT continues to increase in the United States. The indications for therapy are changing towards a view of menopause as a disease, and the indication for hormone therapy towards a modifier of the potential risk of cardiovascular disease and osteoporosis.
In the future, the incidence of morbidity and mortality due to breast cancer for women on estrogen or estrogen/progesterone therapy for longer periods of time may increase. The absence of good clinical trials, to evaluate both the benefits in terms of osteoporosis and cardiovascular disease, and the risks of breast cancer among women on HRT, is extremely unfortunate.
The most likely scenario is that HRT is of benefit for some women at high risk for osteoporosis and coronary heart disease, and not beneficial for women at higher risk for breast cancer. The availability of alternative therapies for both coronary heart disease and osteoporosis further increases the need to determine, in clinical trials, the risks and benefits of hormone replacement therapy. It is now feasible to quantify a woman's risk of cardiovascular disease, osteoporosis, and likely breast cancer. Therapies can be tailored for the individual needs of a woman based on risk evaluation rather than the dassification of menopause as a disease requiring universal hormone replacement therapy.
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